Day One Biopharma Expands to ADCs with $55M Drug Acquisition by Lilu Anderson 19.06.2024 "Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
Ventyx Biosciences: Financial Report Reveals Growth Challenges by Terry Bingman 28.03.2024 Ventyx Biosciences, Inc. (VTYX) is a high-risk investment with negative net income and high debt ratio, but analysts recommend buying ...